Renovaro appoints Simon Tarsh as Interim CFO; outgoing CFO Puche departs

Lunai Bioworks Inc.

Simon Tarsh named Interim CFO effective March 11, 2024; replaces Ms. Puche who leaves after >5 years.
Consulting agreement pays Tarsh PB Advisors $25,000/month plus up to 30% bonus on milestones.
Bonuses tied to timely SEC filings and hiring a permanent CFO before agreement termination.
Term is 6 months, renewable monthly; may be terminated by either party on 30 days' notice.
Tarsh receives 10,000 stock options, vesting if a new CFO is hired prior to termination date.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Ms. Puche

Chief Financial Officer

LNAI · Lunai Bioworks Inc.

Successor: Simon Tarsh
Filed: March 13, 2024, 7:59 PM ET

Ms. Puche, the Company’s outgoing Chief Financial Officer, said: “After more than 5 years at the Company, I am ready for a new phase in my life.

Appointed (interim)

Simon Tarsh

Interim Chief Financial Officer

LNAI · Lunai Bioworks Inc.

Effective: 2024-03-11
Filed: March 13, 2024, 7:59 PM ET

The board of directors (the “Board”) of Renovaro Inc. (the “Company”) appointed Simon Tarsh, age 63, as Interim Chief Financial Officer of the Company, effective March 11, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.9

Ms. Puche departed as Chief Financial Officer at Lunai Bioworks Inc..

Action: departed
Role: Chief Financial Officer

Exact text from the filing

Ms. Puche, the Company’s outgoing Chief Financial Officer, said: “After more than 5 years at the Company, I am ready for a new phase in my life.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Simon Tarsh was appointed as Interim Chief Financial Officer at Lunai Bioworks Inc..

Action: appointed
Role: Interim Chief Financial Officer

Exact text from the filing

The board of directors (the “Board”) of Renovaro Inc. (the “Company”) appointed Simon Tarsh, age 63, as Interim Chief Financial Officer of the Company, effective March 11, 2024.

View on SEC.gov

Lunai Bioworks Inc. filing history →

Source: SEC EDGAR

accession 0001731122-24-000419

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.